PTC THERAPEUTICS, INC.PTCT

時価総額

$59.4億

PER

希少疾患向け医薬品の大手。臨床差別化薬と多様なパイプラインを展開。2020年にTPP創設、2022年10月に約5,000万ドルの株式売却で資金調達。米国・欧州を中心にグローバル展開。

	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss attributable to common stockholders	-51,573,575	-94	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Depreciation and amortization	-	-	-	-	18	26	32	43	64	129	237	76
Non-cash operating lease expense	-	-	-	-	-	-	-	6	7	10	10	8
Non-cash royalty revenue related to sale of future royalties	-	-	-	-	-	-	-	2	23	49	93	182
Noncash Interest Expense, Liability Related to Sale of Future Royalties	-	-	-	-	-	-	-	32	78	73	105	207
Intangible asset impairment	-	-	-	-	-	-	-	-	-	33	218	160
Change in valuation of contingent consideration	-	-	-	-	-	19	48	23	-0	-26	-128	-4
Tangible asset impairment	-	-	-	-	-	-	-	-	-	-	-	4
Loss on sale of fixed assets	-	-	-	-	-	-	-	-	-	-	-	-4
Gain on lease terminations	-	-	-	-	-	-	-	-	-	-	-	2
Gain on lease modification	-	-	-	-	-	-	-	-	-	-	-	5
Gain on sale of priority review voucher	-	-	-	-	-	-	-	-	-	-	-	100
Unrealized (gain) loss on ClearPoint Equity Investments	-	-	-	-	-	-	-	-	-6	-4	-2	8
Unrealized loss on ClearPoint convertible debt security	-	-	-	-	-	-	-	19	-8	-6	-3	-2
Unrealized (gain) loss on marketable securities - equity investments	-	-	-	-	-	-	-	14	2	-8	3	3
Realized loss for the sale of ClearPoint Equity Investment	-	-	-	-	-	-	-	-	-	-	-1	-
Realized loss on ClearPoint convertible debt security	-	-	-	-	-	-	-	-	-	-	-	-1
Realized gain on redemption of marketable securities- equity investments	-	-	-	-	-	-	-	-	-	-	4	-
Issuance of Stock for Milestone Payment	-	-	-	-	-	-	-	-	-	-	30	-
Disposal of asset	-	-	-	-	-	-	-	-	-	-	-	-0
Deferred income taxes	-	-	-	-0	0	-	9	6	0	-34	-47	-56
Amortization of (discounts) premiums on investments, net	-	-2	-2	-2	-1	0	2	-0	-5	-2	2	13
Amortization of debt issuance costs	-	-	0	0	0	1	1	1	2	2	2	1
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	-56	-
Share-based compensation expense	8	19	34	35	31	33	42	70	104	110	102	75
Unrealized foreign currency transaction (gains) losses, net	-	-	-	-1	0	0	12	57	-47	-13	14	10
Non cash foreign currency remeasurement loss on intercompany loan	-	-	-	-	-	-	-	-	-	-17	-	-
Inventory, net	-	-	-	-	6	6	3	-2	-2	7	8	-6
Prepaid expenses and other current assets	760,501	2	2	-1	2	2	9	13	15	52	45	-99
Trade and royalty receivables, net	-56,091	3	7	15	12	30	-12	10	45	48	2	-2
Deposits and other assets	-48,042	0	-0	0	1	1	18	1	0	3	-5	-12
Accounts payable and accrued expenses	5	17	17	4	24	44	27	71	46	28	48	-33
Other liabilities	-	-	-	-	-	-	14	-4	-7	-5	-2	12
Deferred revenue	-	-	-	-	-	7	-1	-8	-4	1	-1	5
Payments on contingent consideration	-	-	-	-	-	-	-	-	-	-10	-	-2
Net cash used in operating activities	-	-	-	-104	-10	-28	-99	-194	-251	-357	-158	-108
Purchases of fixed assets	845,732	5	3	2	3	7	14	18	28	32	28	7
Proceeds from sale of fixed assets	-	-	-	-	-	-	-	-	-	-	-	28
Proceeds from sale of priority review voucher	-	-	-	-	-	-	-	-	-	-	-	150
Purchases of marketable securities - available for sale	-	-	-	-	-	-	-	10	333	53	174	608
Purchases of marketable securities - equity investments	156	248	224	85	81	69	494	1,440	210	23	38	59
Proceeds from Sale of Debt Securities, Available-for-Sale	-	-	-	-	-	-	-	-	843	405	22	550
Proceeds from Sale and Maturity of Marketable Securities	29	107	206	192	175	90	156	944	4	113	132	48
Sale and redemption of ClearPoint Equity Investments	-	-	-	-	-	-	-	-	-	-	3	-
Proceeds from settlement of Clearpoint convertible debt security	-	-	-	-	-	-	-	-	-	-	-	10
Acquisition of product rights and licenses	-	-	-	-	77	8	32	38	57	120	92	68
Net cash provided by (used in) investing activities	-	-	-	104	13	-43	-387	-562	219	290	-177	44
Proceeds from exercise of options	-	1	9	1	2	11	18	70	17	15	24	29
Proceeds from Stock Plans	-	-	-	-	2	3	4	5	6	6	6	5
Repayment of senior secured term loan	-	-	-	-	-	-	12	28	-	-	300	-
Debt extinguishment costs related to senior secured term loan	-	-	-	-	-	-	-	1	-	-	82	-
Proceeds From Sale of Future Royalties	-	-	-	-	-	-	-	650	-	-	1,000	242
Debt issuance costs related to secured term loan	-	-	5	-	-	-	-	-	-	11	0	-
Proceeds from Issuance of Secured Debt	-	-	-	-	40	-	-	-	-	300	-	-
Repayment of Convertible Notes	-	-	-	-	-	-	-	-	-	150	-	-
Payments on contingent consideration obligation	-	-	-	-	-	-	-	-	-	-	-	18
Payment of finance lease principal	-	-	-	-	-	-	-	18	2	1	1	1
Proceeds from stock purchase agreement	-	-	-	-	-	-	-	-	-	50	-	-
Net cash provided by financing activities	-	-	-	1	44	132	613	669	21	168	646	256
Effect of exchange rate changes on cash	-	-	-	-	-	-	-	-	-	-3	3	-7
Net increase in cash and cash equivalents	-	-	-	-	-	-	126	-79	-19	99	314	185
Cash paid for interest	-	-	-	-	-	-	8	10	10	18	36	6
Income Taxes Paid, Net	2,077	-	0	1	1	2	2	26	8	5	14	18
Unrealized (loss) gain on marketable securities, net of tax	-	-	-	-	-	-	-	1	-3	0	1	-0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	-	-	-	-	-	17	77	1	36	-	6
Acquisition of product rights and licenses	-	-	-	-	-	6	11	14	22	33	55	0
Fixed asset additions through tenant improvement allowance	-	-	-	-	-	-	-	-	-	-	-	19
Debt issuance costs related to senior secured term loan	-	-	-	-	-	-	-	-	-	0	-	-
Capital Expenditures Incurred but Not yet Paid	-	-	-	-	-	-	-	1	-	0	-	0